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Abstract:  Introduction: Inhaled short-acting bronchodilators are recommended for the quick relief of bronchospasm 
symptoms in children including those less than five years of age. However, limited safety data is available in this young 
population. 
Methods: Safety data were analyzed from a randomized, double-blind, parallel group, placebo-controlled multicenter, 
study evaluating albuterol HFA 90g or 180g versus placebo three times a day for 4 weeks using a valved holding 
chamber, Aerochamber Plus and facemask in children birth 24 months old with a history of bronchospasm. 
Results: The overall incidence of adverse events (AE) during treatment was: albuterol 90g (59%), albuterol 180g (76%) 
and placebo (71%). The most frequently reported AEs were pyrexia in 7 (24%), 2 (7%), and 3 (11%) subjects in the 
albuterol 180g, albuterol 90g, and placebo groups, respectively. Upper respiratory tract infection (URTI) occurred in 5 
(17%) and 3 (11%) subjects in the albuterol 180g and placebo groups, respectively. Sinus tachycardia occurred in 5 
(17%), 2 (7%) and 2 (7%) subjects receiving albuterol 180g, albuterol 90g and placebo, respectively. One subject in 
each of the albuterol treatment groups experienced drug related agitation and/or restlessness or mild sinus arrhythmia. No 
drug-related QT prolongation or abnormal serum potassium and glucose levels were reported in the albuterol treatment 
groups. 
Conclusion: This study provides additional albuterol HFA safety information for the treatment of children aged birth 24 
months with a history of bronchospasm. 
INTRODUCTION 
  Asthma is an increasingly important cause of chronic 
morbidity affecting approximately 5.5% children less than 5 
years of age in the US, with 3.9% of this age group 
experiencing an asthma attack in the last 12 months [1, 2]. 
This high morbidity has a significant impact in the health 
care system, with asthma in children alone accounting for 
almost 3 million physician visits and 200,000 hospitalizations 
each year [3]. 
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  Albuterol, a short acting beta2- adrenoceptor agonist, is 
widely used for rapid relief of respiratory symptoms in 
accordance with guidelines for current asthma management 
which includes treatment recommendations for children less 
than five years of age [4, 5].
 Treatment of symptoms in this 
very young population can be challenging. In the past, the 
use of nebulized therapy was the preferred method in treating 
asthma symptoms in young children. However, many studies 
including those in children less than 5 years of age have 
demonstrated efficacy, cost-effectiveness and convenience of 
an albuterol MDI used with a spacer or valved holding 
chamber (VHC) [6-11]. 
  Currently there are limited approved treatment options 
for reversible obstructive airway disease in children less than 
4 years of age. An earlier study in children ages 24 to 48 
months with symptoms of reversible obstructive airway 
disease demonstrated no clinically relevant safety signals   
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[12]. However, clinical data in children younger than 24 
months is limited. Therefore the current study was conducted 
primarily to evaluate the safety of albuterol HFA 90g or 
180μg (VENTOLIN HFA is a registered trade name of 
GlaxoSmithKline, Research Triangle Park, NC) 
administered three times daily via a MDI and an 
Aerochamber Plus VHC (Aerochamber Plus is a registered 
trade name of Monaghan Medical, Plattsburgh, NY, USA) in 
symptomatic children between birth and 24 months of age. 
METHODS 
Study Population 
  Patients were recruited from 33 family practice, allergy, 
and pediatric practices in the US. The study (SBO30001) 
was performed in accordance with the ethical principles in 
the Declaration of Helsinki and was consistent with the 
International Conference on Harmonization/Good Clinical 
Practice and applicable regulatory requirements. The 
protocol was approved by the Coast Independent Review 
Board in San Clemente, CA and other center institutional 
review boards as appropriate and each patient’s parent or 
legal guardian provided a signed consent before study 
procedures were undertaken. 
  All children were assessed by the investigators to ensure 
that they met all study eligibility criteria; birth to <24 months 
old, a history of symptoms of bronchospasm that required 
outpatient care, and had received regular maintenance 
asthma pharmacotherapy (except systemic corticosteroids) 
for 3 weeks prior to Visit 1 and/or a short-acting 2-agonist 
prior to Visit 1. In addition all patients were required to be 
symptomatic and to use albuterol on at least 2 of 7 
consecutive days during the screening period. Subjects 
experiencing an exacerbation (defined as an emergency room 
visit, hospitalization, an unscheduled doctor visit/contact 
requiring additional treatment with an asthma medication or 
increased use of patient’s maintenance asthma medication 
other than rescue albuterol) during screening were not 
eligible. Subjects were excluded if they had a history of life-
threatening asthma; other severe concurrent disease; a 
current upper or lower respiratory tract or middle ear 
infection; recent systemic corticosteroid use; premature birth 
(before 34 weeks of gestation); or clinically significant 
laboratory or ECG abnormalities.  Leukotriene modifiers, 
cromolyn and/or nedocromil and inhaled corticosteroids 
were allowed if started prior to screening and remained 
unchanged during the study. All other asthma medications 
were not allowed during the study. 
Study Design 
  This randomized, double-blind, parallel-group, placebo-
controlled study began with a 7 to 28-day screening period, 
followed by a 29-day treatment period. Subjects were 
randomized to receive albuterol inhalation aerosol 90μg or 
180μg or placebo HFA three times daily for a total of 29 
days via a MDI in conjunction with a valved holding 
chamber, the Aerochamber Plus and attached face mask 
(small or medium size). Each subject was dispensed two 
MDI inhalers both containing either albuterol HFA or 
placebo HFA, a holding chamber, face mask (small or 
medium) and administration instructions. Parents/guardians 
were asked to have their child inhale one puff from each of 
the two inhalers three times daily, approximately 4 to 6 
hours apart for 29 days. Open-label albuterol HFA MDI 
(90μg/actuation) with a holding chamber other than the one 
used for study drug or albuterol nebule (2.5  mg/3mL) 
formulations, were provided for rescue use as needed. Study 
medication and rescue albuterol were not permitted for at 
least 4 hours prior to the procedures on Days 1 and 29 during 
which ECGs were performed before and after study 
medication was given in the clinic. Subjects attended the 
clinic during treatment evaluations on Days 1, 8, 15 and 29. 
  The primary goal of this study was to evaluate the safety 
of albuterol inhalation aerosol in patients < 24 months of 
age. Safety measures included the assessment of adverse 
events, signs and symptoms of adrenergic stimulation 
(assessed by certain questions on the Functional Status II (R) 
questionnaire (FSII(R)), [13] the daily diary, and heart rate), 
clinical laboratory assessments for serum potassium and 
glucose, ECG measurements (including QTc interval) and 
physical examination including vital signs. An independent 
electrocardiographer, blinded to treatment assignments 
interpreted the ECGs. The cut-off for the QTc interval was 
chosen as 460 msec based on suggested QTc values 460 
msec as prolonged in children aged 1-15 years. 
  Blood samples were collected on day 1 and day 29. 
Serum potassium and glucose were evaluated by a 
centralized laboratory (Quest Laboratory). Safety was 
assessed by the frequency of AEs, abnormal laboratory, 
ECGs evaluating heart rate, QT/QTc interval, blood pressure 
and other ECG interval measurements and any signs and 
symptoms of adrenergic stimulation. Each investigator was 
required to determine the causality assessment of the 
relationship of the event to the study drug and whether it 
constituted a serious adverse event. 
  Twenty-four hour daily asthma symptom scores were 
documented by the patient’s care-giver in the diary record 
provided at the screening visit. Other efficacy parameters 
also noted in the diary record included 24-hour rescue 
albuterol use, nighttime airway symptom scores, percentage 
of symptom-free 24-hour days, daytime symptom scores, 
percentage of nights with no awakenings due to symptoms 
requiring albuterol treatment, use of rescue systemic 
corticosteroid, and/or inhaled corticosteroids during the 
study, and the number of exacerbations. Study personnel 
checked the diary record for completion and compliance at 
all clinic visits. 
  Study medication was supplied to the investigators as 2 
inhalers (double blind canisters labeled Can A and Can B) 
for administration via MDI with HFA propellants, with 
instructions to test spray each MDI four times before use the 
first time and inserting into holding chamber. Rescue 
medication was provided separately and all study medication 
use was documented in a patient diary record provided at 
study start. Patient guardians were advised to return all 
clinical supplies after each visit. Treatment compliance was 
calculated for each subject as a proportion of the number of 
doses used per expected number of doses used for the 
double-blind treatment period. 
Statistical Analysis 
  Approximately 80 subjects (25 per treatment group) were 
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would complete the study. This study was conducted 
primarily to assess safety, thus the sample size was not 
expected to provide enough statistical power to detect 
significant differences in the efficacy parameters between 
any two treatment arms. Analyses of the efficacy endpoints 
and FSII(R) total scores were performed for descriptive 
purposes only. The primary efficacy measure was mean 
change from baseline to the endpoint (the average over the 4-
week treatment period) in 24-hour daily asthma symptom 
scores. Symptoms including cough, wheeze, and shortness of 
breath were rated by the parent/guardian on a scale of 0 (no 
symptoms) to 3 (severe symptoms that restricted normal 
daily activities or kept patient awake most of the night). 
Other measures included 24-hour rescue albuterol use, day 
and nighttime asthma symptom scores, percentage of 
symptom-free 24-hour days, nighttime awakenings due to 
symptoms, use of rescue systemic or inhaled corticosteroids, 
and the number of subjects with exacerbations. 
  All analyses were conducted on the intent-to-treat (ITT) 
population, which comprised all randomized subjects who 
received at least one dose of study medication. Two-sided 
statistical tests with a 0.05 level of significance were used 
and 95% confidence intervals were provided. Analyses of 
24-hour asthma symptom scores, and FSII(R) total scores 
were performed using analysis of covariance, with baseline, 
age, gender, and region (grouping of investigational sites by 
geographic location), and concurrent medication use for 
asthma (subjects receiving a fixed dose of inhaled 
corticosteroids and/or leukotriene modifiers, or not) as the 
covariates, in addition to treatment effect. No inferential 
statistics were provided for any of the other efficacy 
measures. Twenty-four hour asthma symptom scores were 
summarized by concurrent medication use for asthma. 
FSII(R) total scores were summarized for those subjects for 
whom the same parent/guardian completed the questionnaire 
at all visits. No statistical testing was conducted on safety 
measures, which were summarized using descriptive 
statistics. All statistical analyses were performed using SAS 
(SAS Institute, Cary, NC) software version 8. 
RESULTS 
Patient Demographics and Disposition 
  A total of 118 subjects were screened for this study, of 
which 32 were not randomized due to failure to meet entry 
criteria, including not meeting rescue albuterol use 
requirements or symptom criteria prior to Visit 2, a current 
respiratory infection, lack of compliance or withdrawing 
consent; or an adverse event. Demographic characteristics of 
the 86 randomized subjects were similar across all groups 
(Table 1). The mean age of onset of asthma symptoms was 
5.5 months, and the most commonly identified risk factors 
for asthma were family history of asthma (94%), history of 
eczema (24%), year round hay fever (15%), seasonal hay 
fever (15%) and history of food allergy and history of sinus 
infection (each at 13%). Very few subjects (4, 1 and 3 
subjects in the placebo and albuterol HFA 90g and 180g 
groups, respectively) discontinued from the study (Table 1). 
Approximately half of the subjects in each treatment group 
used concurrent asthma medications. Budesonide and 
montelukast use were most frequently reported. Mean 
compliance with study medication was high in all groups 
(89.5-92%). 
Safety 
  A total of 59 subjects (69%) reported at least one adverse 
event, [20 (71%), 17 (59%) and 22 (76%) subjects in the 
placebo, albuterol HFA 90g and 180μg groups, 
respectively]. The most frequently reported events were 
pyrexia or fever (3, 2, and 7 subjects in the placebo, albuterol 
HFA 90g and 180μg, groups, respectively), nasopharyngitis 
(3, 2 and 4 subjects in the placebo, albuterol HFA 90g and 
Table 1.  Demographics and Disposition of Subjects 
 
  Placebo 
(N = 28) 
Albuterol HFA 
90μg TID (N = 29) 
Albuterol HFA 
180μg TID (N = 29) 
Gender 
Male, n (%)  19 (68)  19 (66)  21 (72) 
Female, n (%)  9 (32)  10 (34)  8 (28) 
Age, mean months (range),  13.9 (3-23)  14.1 (3-22)  16.3 (6-23) 
Ethnic origin, n (%) 
White  15 (54)  17 (59)  13 (45) 
American Hispanic  6 (21)  7 (24)  9 (31) 
Black  7 (25)  5 (17)  6 (21) 
Other 0  0  1  (3) 
Concurrent asthma medications, n (%)  15 (54)  14 (48)  15 (52) 
Number Discontinued from Study, n (%)  4 (14)  1 (3)  3 (10) 
Due to Lack of efficacy  4 (14)  0  2 (7) 
Due to Consent Withdrawn  0  1 (3)  0 
Due to Other  0  0  1 (3) 
HFA, hydrofluoroalkane; TID, three times daily; ICS, inhaled corticosteroids. Albuterol HFA in Children Birth to <24 Months Old  The Open Respiratory Medicine Journal, 2009, Volume 3    103 
180μg, groups, respectively), upper respiratory tract 
infection (3 and 5 subjects in the placebo and albuterol HFA 
180μg groups, respectively) and sinus tachycardia (2, 2, and 
5 subjects in the placebo, albuterol HFA 90g and 180μg 
groups, respectively) and teething (3,4, and 1 subjects in the 
placebo and albuterol HFA 90g and 180μg groups, 
respectively). One subject in the placebo group experienced 
a serious adverse event (asthma exacerbation) which 
occurred 28 days after study medication administration and 
was considered by the investigator to be moderate and most 
likely secondary to subject’s viral upper respiratory tract 
infection with no causal association with study drug. This 
patient withdrew from the study due to lack of efficacy. 
  No clinically significant differences were observed 
between treatment groups in laboratory evaluations, vital 
signs or physical examination. Although there were a few 
shifts to high or low in blood glucose or serum potassium 
levels, no cases of drug-related abnormalities were reported 
in the albuterol HFA treated groups. Adrenergic stimulation 
was assessed using 7 individual items (sleep well, content/ 
cheerful, act moody, unusually irritable, sleep through the 
night, unusually difficult and react by crying) from the 
FSII(R) questionnaire. Higher scores reflected a better 
functional status. Mean scores increased for all items in each 
treatment group with the exception of the “content/cheerful” 
score, which remained high and unchanged, and the score for 
“unusually irritable and difficult ” that changed slightly in all 
treatment groups. No evidence of adrenergic stimulation was 
derived from these scores. 
Cardiovascular Safety 
  Across all groups, 82-86% subjects had normal ECGs at 
screening. Electrocardiograms were evaluated by a central 
cardiologist as normal, abnormal not clinically significant or 
abnormal clinically significant. Additionally ECGs at 
randomization visit 2 post-dose, and week 4 pre and post-
dose were compared for clinically significant changes with 
respect to screening or randomization pre-dose or week 4 
pre-dose. Of the 8 subjects that prematurely discontinued the 
study, 6 had ECGs performed, none of which were abnormal 
when compared with baseline measurements. 
  At screening (Visit 1), 1 subject in the placebo group, 
(sinus bradycardia), 4 subjects in the albuterol HFA 90g 
group (1 with sinus rhythm and biventricular hypertrophy, 1 
with right ventricular hypertrophy and 2 with sinus 
tachycardia) and 2 subjects (sinus tachycardia) in the 180g 
group had abnormal clinically significant ECGs. 
  At randomization visit 2 post-dose six subjects each in 
the placebo (4 with sinus tachycardia, 1 with sinus rhythm 
non-specific T-wave abnormality and 1 with low right atrial 
rhythm abnormality and sinus tachycardia) and albuterol 
180g group (5 with sinus tachycardia of which 1 also had 
left axis deviation and 1 subject had sinus bradycardia) and 3 
subjects in the albuterol 90g (1 each with sinus tachycardia 
or bradycardia and 1 with sinus tachycardia and 1
st degree 
AV block) showed a clinically significant change as 
compared to visit 2 pre-dose 
  At Week 4 visit pre-dose, five subjects in the albuterol 
HFA 180μg group had a clinically significant change in 
ECG when compared to visit 2 pre-dose (4 subjects had 
sinus tachycardia 1 subject had bradycardia) One subject in 
the placebo group had a clinically significant prolonged QT 
which resolved at Week 4 post dose. 
  Pre and post dose ECG comparisons at week 4 showed 
ten subjects, five in each of the albuterol HFA 90g and 
180g groups and none in the placebo group with a clinically 
significant change in ECG. In the albuterol 90g three 
subjects had ECG voltage measurements consistent with 
ventricular hypertrophy as determined by the independent 
cardiologist [either right, left (with sinus arrhythmia) or 
biventricular hypertrophy with right axis deviation]. Two of 
these subjects had normal findings with a repeat ECG and 
ECG cardiology consult. The third subject was contacted 
but did not return for follow-up. One subject had sinus 
arrhythmia (potentially drug-related) that resolved in a week 
and 1 subject had increase PR interval. In the albuterol 
180g group 4 subjects had tachycardia and 1 subject had 
sinus bradicardia. None of the reported eposides of 
tachycardia was felt by the investigators to be related to 
albuterol HFA treatment. 
  No subjects had a QT or QTc interval >460 msec. Mean 
heart rate, QT and PR intervals and QRS durations 
summarized in Table 2, were similar to baseline values at 
week 4. No significant differences were observed in drug 
related adverse events that occurred during the study. 
Efficacy 
  Although this study was not powered for efficacy, 
changes from baseline to endpoint in efficacy parameters 
were evaluated. At screening, mean 24-hour asthma 
symptom scores were low (noticeable symptoms, but no 
interference with daily activities or sleep) and similar across 
treatment groups. Asthma scores declined slightly in each 
group over 4 weeks of treatment. No difference between the 
two treatment groups was observed in daytime and nighttime 
symptom scores. All groups showed a favorable change in 
the percentage of symptom free 24-hour days, rescue 
albuterol use and nighttime awakenings compared to 
baseline; however the differences were not significant 
between treatment groups. 
DISCUSSION 
  Albuterol sulfate inhalation aerosol is well established in 
the treatment and prevention of reversible obstructive 
airways disease and is currently approved in children over 4 
years of age. However, there is limited information available 
for albuterol HFA in younger children. This study extends 
the safety profile of albuterol HFA for the treatment of 
respiratory symptoms in children birth to <24 months of age. 
  Asthma treatment guidelines state that metered-dose 
inhaler with auxiliary devices and face masks can be used in 
children less than 4 years of age and recommend nebulizers 
for children under 24 months of age and children of all ages 
who cannot use MDIs with auxiliary devices [5, 6]. Recent 
studies have shown the metered-dose inhaler with spacer to 
be an effective alternative to nebulizers in the administration 
of beta2-agonists for the treatment of children with severe or 
potentially severe acute asthma in the emergency department 
[14, 15]. MDI with valved holding chamber offers practical 
advantages including less set-up time, portability, the 
capacity for home use, and no need for daily disinfection 
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holding chamber and spacer provides a greater distribution 
throughout the lungs due to smaller particle production, and 
significantly reduced amounts of large particle deposition in 
the oropharynx [20, 21]. 
  The doses selected in this study were similar to 
recommended doses per the Ventolin
® HFA package label 
and are consistent with asthma treatment guidelines, the 
doses used for nebulization and normal clinical practice [5, 
18, 22, 23]. The medications were given three times a day 
for 29 days as part of the study design in order to make 
dosing easier on the care giver and to better assess safety. 
  Studies of inhaled bronchodilator safety in children 
younger than 24 months old are limited. In a comparative 
study, children 2 years and older with asthma exacerbations 
treated with beta-agonists via a MDI and spacer required 
shorter treatment times in the emergency department, and 
smaller increases in heart rate than those treated with a 
nebulizer [24]. Another recent study in children less than 5 
years of age demonstrated a significant heart rate increase in 
the salbutamol aerosol therapy via a jet nebulizer when 
compared to the MDI with spacer [25]. 
  Electrocardiographic adverse effects have been reported 
with the use of beta-agonists in adults and children. The 
stimulation of the cardiac -adrenergic receptors could cause 
dose related pharmacologically predictable adverse effects 
[26]
  such as tachycardia, and arrhythmias [27, 28]. 2 
mediated electrolyte disturbances include hypokalemia from 
increased cellular influx of potassium into cells and 
hyperglycemia due to increased glycogenolysis [27-29]. A 
14 day study with high dose (1000 μg 4 times daily) inhaled 
albuterol treatment demonstrated that improvement in 
bronchodilatation (FEV1, maximal FEV1  ) is maintained 
and that there was attenuation in systemic adverse effects 
(glucose or potassium abnormalities, tremor and 
palpitations) [30].
 A recent study of children 5 to 17 years 
old attributes the higher and significant change in heart rate 
after nebulizer aerosol treatment to greater deposition, 
pooling and delayed absorption of albuterol in the upper 
airway [31]. Another study showed no significant increase in 
QTc prolongation in adult subjects with acute asthma 
exacerbations treated with doses of 400 or 600 μg 
salbutamol via MDI with spacer at 10-minute intervals over 
3 hours [32].
 In a recent study in 2-4 year old children treated 
with either albuterol HFA 90μg or 180μg or placebo 3 times 
a day for 4 weeks, there were no clinically relevant 
differences in the mean change from baseline in the QT 
interval between treatment groups [12].
 
  In our study, children aged birth to <24 months with a 
history of bronchospasm treated with albuterol HFA MDI 
Table 2.  Summary of ECG Measures, Mean (Change from Baseline) 
 
ECG Measure  Placebo 
(N=28) 
Albuterol HFA 
90μg TID (N=29) 
Albuterol HFA 
180μg TID (N=29) 
Heart Rate (bpm) 
Baseline
a 127.2  132.4  128.6 
Week 4 Pre-dose
c  126.4 (-2.0)  126.3 (-5.4)  128.1 (-1.6) 
Week 4 Post-dose
c  123.9 (-4.5)  129.0 (-2.9)  132.7 (3.0) 
QT Interval (msec) 
Baseline
a 279.1  275.4  273.4 
Week 4 Pre-Dose
c  279.8 (2.3)  279.1 (0.7)  274.9 (1.0) 
Week 4 Post-dose
c  279.0 (1.5)  279.0 (2.3)  276.1 (2.3) 
QTc Interval
b (msec) 
Baseline
a 357.1  357.7  350.7 
Week 4 Pre-Dose
c  357.8 (1.7)  356.5 (-4.4)  352.2 (0.0) 
Week 4 Post-dose
c  354.0 (-2.0)  358.2 (-0.7)  358.5 (6.3) 
PR Interval (msec) 
Baseline
a 111.6  116.5  111.3 
Week 4 Pre-Dose  115.4  118.5  110.7 
Week 4 Post-dose  114.4  118.2  114.1 
QRS Duration (msec) 
Baseline
a 67.5  66.2  66.2 
Week 4 Pre-Dose  68.3  67.4  66.3 
Week 4 Post-dose  68.4  66.8  67.2 
HFA, hydrofluoroalkane; TID, three times daily. 
aBaseline, value obtained at Screening Visit. 
bCorrected for heart rate using Fredericia's formula. 
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90g or 180g with a valved holding chamber three times 
daily for 4 weeks, demonstrated no clinically relevant safety 
issues. The overall incidence of adverse events possibly 
related to adrenergic stimulation in the current study was low 
across the treatment groups and did not cause subject 
withdrawal from study. Episodes of sinus tachycardia were 
slightly higher in the albuterol 180g group, almost half of 
which were not considered clinically significant by the 
independent cardiologist and those that were clinically 
significant were subjects in distress who were crying during 
the ECG procedure. Three subjects exhibited ECG voltage 
measurements suggestive of ventricular hypertrophy. These 
were not confirmed upon repeat ECG measurements or 
consultation. Electrolyte imbalances such as hypokalemia 
and hyperglycemia were not experienced with albuterol HFA 
treatment. There were no clinically relevant differences 
between treatment groups in cardiovascular parameters such 
as, blood pressure, or other ECG findings over the treatment 
period. Albuterol HFA treatment demonstrated a slight 
improvement in most efficacy parameters, like the mean 24-
hour asthma symptom score, percentage of symptom free 24-
hour days, rescue albuterol use, and nighttime awakenings 
though none were significantly different from placebo. 
Statistical differences were not demonstrated for the efficacy 
outcomes primarily due to the study not being powered to 
show differences and mildness of the subject symptoms at 
screening. 
  Although abuterol HFA is currently not indicated for use 
in children less than 4 years of age, it is recognized that 
physicians sometimes prescribe this medication in this 
younger age population. As there are very few studies in 
children less than 2 years of age, the aim of this study was to 
examine the safety of albuterol HFA MDI in this age group. 
Due to the uniqueness of this population and the challenges 
of safety parameter collection, a patient may or may not 
experience the events observed in this study. Caution needs 
to be exercised in prescribing the appropriate therapy 
because of potential complications during an episode of 
bronchospasm in this age group. Moreover, monitoring the 
patient closely during treatment and providing education for 
the proper use of MDI-spacer-facemask combination is also 
of utmost importance. In conclusion, this study in children 
less than 24 months old with a history of symptoms 
compatible with bronchospasm demonstrated no clinically 
relevant safety signals during prolonged patient treatment in 
either treatment group. 
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